14 clinicians with mental illness share how they ask patients about mania, depression, psychosis, OCD, panic disorder, addiction, trauma, and suicide.

Does psychiatry keep making the same mistakes? Edward Shorter gives us a historical perspective. 

0.25 CME Credits. Psychiatric news covered in this episode: FDA Grants Priority Review for MDMA Therapy, Benzodiazepine Withdrawal Perils, Lithium: Good for Bones?, Iloperidone Added to Anti-Psychotics with Mania Efficacy, Transdiagnostic Sleep and Circadian Treatment, A Door Closes for Clozapine-Resistant Schizophrenia, Therapy for Multi-Trauma PTSD.

Viibryd has gone generic, but is it worth prescribing? We review all there is to know about vilazodone in this update from our #1 most read article of 2023.

All sorts of medications are prescribed for anxiety in older adults. Today, we look at when and how to discontinue them.

Here's a Throwback Thursday episode originally cast in March of 2021, where we're going to look at the question of whether adding a z hypnotic improves antidepressant response. And stay tuned to the very end where I'm going to update it with new research. We all know that when you sleep better, you feel better.

Dosing is not a collaborative venture when it comes to controlled substances, and here we look for the safe upper limits of stimulant dosing.

The release of the fast-acting antidepressant Auvelity got us thinking about an older strategy to speed up antidepressants: benzodiazepines. So we're bringing you this Thursday throwback, do benzodiazepines treat depression? Benzos and sleep meds rarely earn a mention in textbooks on depression these days, but that has not always been the case. (Part 1 of a 2 part series)

Auvelity, a new rapid acting medication for depression, is a branded combination of two generic drugs. We look at its side effects, addictive potential, and whether you can just use the generic components.

Auvelity, a new rapid acting medication for depression, is a branded combination of two generic drugs. We look at how it works and the clinical trials, including new data in treatment resistant depression